Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Merrimack Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.13 |
52 Week High | US$15.89 |
52 Week Low | US$11.53 |
Beta | 1.42 |
1 Month Change | 2.79% |
3 Month Change | 3.07% |
1 Year Change | 21.72% |
3 Year Change | 134.21% |
5 Year Change | 140.16% |
Change since IPO | -74.95% |
Recent News & Updates
Recent updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment
Dec 02Merrimack Pharmaceuticals reports Q3 results
Nov 05Shareholder Returns
MACK | US Biotechs | US Market | |
---|---|---|---|
7D | 0.07% | 0.02% | 1.2% |
1Y | 21.7% | 6.7% | 20.6% |
Return vs Industry: MACK exceeded the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: MACK underperformed the US Market which returned 26% over the past year.
Price Volatility
MACK volatility | |
---|---|
MACK Average Weekly Movement | 0.7% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MACK has not had significant price volatility in the past 3 months.
Volatility Over Time: MACK's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | n/a | Gary Crocker | www.merrimack.com |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals, Inc. Fundamentals Summary
MACK fundamental statistics | |
---|---|
Market cap | US$223.75m |
Earnings (TTM) | -US$1.35m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-166.2x
P/E RatioIs MACK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MACK income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$1.35m |
Earnings | -US$1.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.091 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did MACK perform over the long term?
See historical performance and comparison